medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (6)


Frequency of hepatitis C virus infection in a single institution in Mexico with a focus on birth-cohort population

Baptista-González H, Noffal-Nuño VM, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 846-852
Archivo PDF: 148.86 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.

  2. Mendez-Sanchez N, García-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, Kobashi-Margáin RA, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

  3. Mendez-Sanchez N, Aguilar-Ramírez RJ, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Avila F, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-3.

  4. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003- 2013. Clin Infect Dis 2016; 62: 1287-8.

  5. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300.

  6. Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: A systematic review and meta-analysis. PLoS One 2015; 10: e0141715.

  7. Gutierrez JP, Sucilla-Perez H, Conde-Gonzalez CJ, Izazola JA, Romero-Martinez M, Hernandez-Avila M. Decrease of HCV seroprevalence in Mexico: Results from the National Health and Nutrition Survey 2012. Sal Pub Mex 2016; 58: 25-32.

  8. Vatcheva KP, Beretta L, Pan JJ, Fallon MB, Mccormick JB, Fisher-Hoch SP. Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiology & Infection 2016; 144: 297-305.

  9. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(Rr-4): 1-32.

  10. Valdespino JL, C-GlC, Olaiz-Fernaìndez G, Palma O, Kershenobich D, Sepuìlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿un problema de salud pública emergente? Salud Pub (Mex) 2007; 49: S395-S403.

  11. Alfaleh FZ, Nugrahini N, Maticic M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, et al. Strategies to manage hepatitis C virus infection disease burden - volume 3. J Viral Hepat 2015; 22(Suppl. 4): 42-65.

  12. Mendez-Sanchez, Baptista-Gonzalez H, Sanchez-Gomez RH, Bordes-Aznar J, Uribe-Esquivel M. The prevalence of hepatitis B and C in blood donors in a 3rd-level hospital of Mexico City. Sal Pub Mex 1999; 41: 475-8.

  13. Mendez-Sanchez N, Gutierrez-Grobe Y, Kobashi-Margain RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9 (Suppl. 1): 27-9.

  14. Vivas-Arceo C, Benavides SA, De Jesús Trujillo J, Panduro A, Rivas-Estilla AM. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res 2003; 25: 115-23.

  15. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology 2007; 50: 1-8.

  16. Gomez GC, Chavez TNC, Ponciano RG, Uribe M, Mendez SN. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Ann Hepatol 2015; 14: 807-14.

  17. Carrion AF, Martin P. Viral hepatitis in the elderly. Am J Gastroenterol 2012; 107: 691-7.

  18. Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, Sanchez-Lara K, Ponciano-Rodriguez G, Uribe-Ramos F, et al. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol 2006; 5: 276-80.

  19. Ladron-de Guevara L, Gomez N, Vazquez-Cantarell M, Garcia- Mendez S, Di Silvio M. Prevalence of and risk factors for hepatitis C in blood donors. Rev Gastroenterol Mex 2002; 67: 11-6.

  20. Mohd Hanafiah K, Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

  21. Alonso M, Guzmán A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health 2015; 60: 789-98.

  22. Sosa-Jurado F, Santos-López G, Guzmán-Flores B, Ruiz- Conde JI, Meléndez-Mena D, Vargas-Maldonado MT, Martínez- Laguna Y, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 2010; 7: 18-23.

  23. Soza A, Riquelme A, Arrese M. Routes of transmission of hepatitis C virus. Ann Hepatol 2010; 9(Suppl.): 33.

  24. Lopez-Balderas N, Bravo E, Camara M, Hernandez-Romano P. Seroprevalence of hepatitis viruses and risk factors in blood donors of Veracruz, Mexico. J Infect Dev Ctries 2015; 9: 274-82.

  25. Miller LS, Rollin F, Fluker SA, Lundberg KL, Park B, Quairoli K, Niyibizi, NK, et al. High-yield birth-cohort hepatitis C virus screening and linkage to care among underserved African Americans, Atlanta, Georgia, 2012-2013. Public Health Rep 2016; 131 (Suppl. 2): 84-90.

  26. Vera de Leon L, Juarez A, Diaz GM, Bazan PJ. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005; 70: 25-32.

  27. Silva I, Carvalho Filho R, Feldner AC, Zaros I, Silva AE, Ferraz ML. Poor response to hepatitis C treatment in elderly patients. Ann Hepatol 2013; 12: 392-8.

  28. Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, et al., Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014; 20: 10984-93.

  29. Contreras AM, Ochoa-Jimenez RJ, Celis A, Mendez C, Olivares L, Rebolledo CE, Hernandez-Lugo I, et al, High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion 2010; 50: 1335-43.

  30. Williams D, Williams D, Pitre E, Ford C, Polisena J, Weeks L. CADTH Health Technology Assessments, in Screening for Hepatitis C Virus: A Systematic Review and Meta-analysis - Project Protocol. 2015, Canadian Agency for Drugs and Technologies in Health 2015 (c) CADTH: Ottawa (ON).

  31. Diez-Padrisa N, Castellanos LG. PAHO Viral hepatitis Working Group. Viral hepatitis in Latin America and the Caribbean: a public health challenge. Rev Panam Salud Publica 2013; 34: 275-81.

  32. World Hepatitis Alliance. Global Community Hepatitis Policy Report. 2014.

  33. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar MV. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013; 13: 181.

  34. Mozalevskis, Eramova I, Safreed-Harmon K, Lazarus JV. Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012. Euro Surveill 2016; 21.




2020     |     www.medigraphic.com